Opinion|Videos|January 15, 2025
Polycythemia Vera: Treatment Options
Author(s)Julie Huynh-Lu, P.A.
panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection based on individual risk factors and symptoms, while patients can actively participate in their care through lifestyle modifications and regular monitoring of blood counts, symptoms and cardiovascular risk factors to achieve both immediate symptom relief and long-term disease control.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly review the currently available treatment options for PV. How do they work? And how do you choose the right treatment?
- Is there a treatment for PV overall, or are there just treatments for individual symptoms?
- What are the short- and long-term goals for PV?
- How can patients be involved in managing their PV?
- How do you assess treatment response and monitoring of patients with PV?
Advertisement
Related to this article
Medicare will move ostomy supplies to eight national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Advertisement
Advertisement
Trending on CURE
1
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
Top 5 Takeaways From ESMO 2026 That Patients Should Know
4
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
5